China NMPA grants breakthrough therapy designation to Abbisko Therapeutics’ irpagratinib to treat hepatocellular carcinoma: Shanghai Tuesday, May 27, 2025, 10:00 Hrs [IST] Abbis ...

The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy ...

Abbisko Cayman Limited ( ($HK:2256) ) has provided an announcement. Abbisko Therapeutics has announced that its small molecule FGFR4 inhibitor, ...

Vor Bio to wind down, halting cell therapy trials and shedding most staff Focusing on NGM120 means setting aside aldafermin, an engineered FGF19 hormone with a troubled history. The asset had ...

IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)—The IKF-IMMULAB trial. Trastuzumab ...

Incomplete responders to obeticholic acid had significant increases from baseline in fibroblast growth factor 19 vs. those on placebo. They also had lower fibrosis scores and reductions in ...

The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a Phase 1 study".

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648.

FGF19 hormone has pleiotropic metabolic functions, including the modulation of insulin sensitivity, glucose/lipid metabolism and energy homeostasis. On top of its physiological metabolic role, FGF19 ...

ABSK-011 was well-tolerated in HCC pts. BID cohorts demonstrated a promising antitumor activity with an ORR of 40.7% in FGF19+ HCC pts with prior therapies, which suggests that ABSK-011 may have ...